Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00710580 · ClinicalTrials.gov registry record · Phase 3
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
NCT00710580 is a Phase 3 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 350 participants.
The verdict
NCT00710580, a Phase 3 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
Study Summary
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
Interventions
- DRUG placebo
- BIOLOGICAL etanercept
- BIOLOGICAL ABT-874
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00710580
The ClinicalTrials.gov registry entry for NCT00710580 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00710580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00710580 about?
NCT00710580 is a clinical study titled "Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis". Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
What is the current status of trial NCT00710580?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2008-07. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00710580?
The interventions under investigation include: placebo (DRUG), etanercept (BIOLOGICAL), ABT-874 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00710580?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.